, and intracellular calcium mobilization.
INTRODUCTION
Chemokines belong to a large family of small, basic proteins (approximately 8 -17 kDa) that bind to and activate G protein-coupled receptors (GPCRs), and elicit a series of physiological responses including cell migration. CCR1 binds and responds to multiple endogenous proinflammatory chemokines such as MIP-1α/CCL3, RANTES/CCL5, MCP-2/CCL8, MCP-4/CCL13 and HCC-1/CCL14 [1] . Among these chemokines, HCC-1 is specific for receptor CCR1 present in high concentrations in normal human plasma. vMIP-II, a broad-spectrum chemokine receptor antagonist encoded by K4 sequence in human herpes virus 8 genome, is capable of interacting with both CC and CXC chemokines receptors [2] . Several peptides derived from vMIP-II have been studied for their ability to block ligand/receptor interaction.
Chemokine/chemokine receptor interactions have been validated to be targets owing to their involvement in physiopathological disorders and development of many diseases. In addition to induce cell migration, evidences have suggested that CCR1 is involved in bone remodeling by mechanical loading [3] , and the regulation of stemness of adipose tissue derived stromal cells (ADSCs) [4] . It has been shown that, CCR1, in terms of disease progression, plays a significant role in the pathogenesis of multiple sclerosis [5] , rheumatoid arthritis (RA) [6] , graft-versus-host disease (GVHD) [7] , and allergic encephalomyelitis [8] . For the treatment of these diseases, antagonism of CCR1 has become an appealing therapeutic target.
It is well known that several small molecule drug discovery efforts on chemokine receptors, such as CXCR4, CCR1 and CCR5, have been undertaken over the last several years [9] . Numerous articles have been published, at the same time, on the interactions between CCR1 and its ligands with small molecule antagonists. A number of CCR1 antagonists , including CP-481715, BX471 and AZD-4818, have been described up to now [9, 10] .
In this work, structure-based sequence alignment, simulated peptide-cut and bioinformatics analysis were used to search for peptide derived from vMIP-II with the function to block ligand/CCR1 interaction. To prepare peptide C18P, protease was used for the first time to digest vMIP-II. We evaluated the potential of C18P to dose-dependently inhibit the binding of MIP-1α and RANTES to CCR1-expressing cells, blocking HCC-1 induced [ 35 S]GTPγS binding, plus ligands induced intracellular calcium mobilization and chemotaxis. The aim of the present study was to screen a peptide containing 18 amino acids (C18P) derived from vMIP-II, and to further evaluate its potential as an efficient antagonist of CCR1. 
EXPERIMENTAL

Cells and cell culture
Human CCR1-transfected HEK293 cells were generated as previously described [11] , and maintained in Geneticin for selection, split twice per week, discarded after passage 12. The human monocytic cell line (THP-1) was maintained in RPMI 1640 medium and split 24 h before use. RPMI 1640 medium supplemented with fetal bovine serum (10 %), L-glutamine (2 mM), Hepes (10 mM), penicillin (100 U/ml), Lglutamine (2 mM), and streptomycin (50 μg/ml).
Screening and preparation of C18P
After sequence alignment, 38 kinds of proteases offered by PeptideCutter were utilized to the simulated peptide-cut of vMIP-II. Peptide fragments including the conserved residues were picked out and analyzed using ProtParam. Vector NTI Advance software was used to build a computer model of final option based on the solved structure of vMIP-II. In line with the result of screening, suitable effective protease was chosen to digest vMIP-II under the most effective condition. Dialysis, gel filtration chromatography and repeated high performance liquid chromatography were performed together to purify the final selected peptide. The molecular weight of C18P was tested using mass spectrometry.
Chemokine and C18P binding studies
Radioligand binding assays on human CCR1-transfected HEK293 cells were conducted utilizing scintillation proximity assay (SPA) protocol. Cells were suspended in the assay buffer [50 mM Hepes (pH7. 4 I-labeled RANTES (specific activity, 2,200 Ci/mmol) and radioactivity was counted using a scintillation counter (PerkinElmer Life Sciences, USA). Non-specific binding in competition studies was determined using 100 nM unlabeled MIP-1α or RANTES. Similar procedures were performed in the presence of 
Isolation of human peripheral blood mononuclear cells (PBMCs)
Heparinized sterile syringes were prepared for collecting human whole blood from healthy donors. Then immediately transferred diluted cell suspension to conical centrifuge tubes and centrifuged 30 min at 580 × g, 20 °C. PBMCs were harvested from the interface and washed twice by adding excess hanks balanced salt solution (HBSS) and centrifuging 10 min at 280 × g, 20 °C. Hypotonic lysis was used to remove any remaining red blood cells. Collected cells were then subjected to slow speed centrifugation (150 × g) to remove extra platelets. Cell toxicity of C18P was determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as previously described [13] .
Chemotaxis assay
Measurement of PBMCs chemotaxis was conducted in 24-well ChemoTx microplates (Neuroprobe, USA) as follows. Briefly, 10 ng/ml different chemokines were loaded onto lower wells of the chamber filling with chemotaxis assay buffer [RPMI 1640 containing 0.5 % bovine serum albumin (BSA) and 0.1 % antibiotic] in a final volume of 600 μl. The 5 μm pore polycarbonate filter (Neuroprobe, USA) was placed between the upper and lower wells of the chamber, and PBMCs (2 × 10 6 cells/ml) in a volume of 100 μl were loaded onto the filter in the presence or absence of different concentrations of C18P. Cell migration proceeded for 2 h in a humidified incubator at 37 °C with 5 % CO 2 , then the chamber was disassembled. The cells migrating into the lower chamber were collected and then transferred to 96-well plates (Corning, USA). The number of cells was quantified as previously described [14] .
Calcium mobilization experiments
PBMCs were diluted to 2 × 10 6 cells/ml with RPMI 1640 media in 24-well plates (Corning, USA).Then, chemokine or C18P was added to the cells for 24 h at 37 °C with 5 % CO 2 in a humidified incubator. After washing twice and suspending at 1 × 10 7 cells/ml in serum-free RPMI 1640, PBMCs were loaded with 10 μM (final concentration) Fluo-3/AM (Sigma, USA) for 30 min at 37 °C with 5 % CO 2 in the dark. The cell suspension was then filtered after washing three times with HBSS containing 10 mM Hepes. Calcium mobilization was tested using a flow cytometry FACSCalibur (BD Biosciences, USA) at excitation wavelengths of 488 nm, and an emission wavelength of 530 nm. To evaluate selectivity, PBMCs were loaded with Fluo-3/AM and stimulated with ligands specific for non-CCR1 receptors (Table 1) , respectively.
Data analysis
Data are from replicate experiments and expressed as mean ± SD. Student's t test was used to evaluate the data. A value of p < 0.01 or p < 0.05 was considered to be statically significant. 
Table1: Chemokines used in this study
RESULTS
Sequence alignment and structure analysis
A sequence alignment of vMIP-II with several CCR1 binding chemokines is shown in Figure 1 . As illustrated in the picture, conserved residues (binding sites), K45 and R46, are located in Cterminal near the core of the skeleton. The CCR1 binding model represents that a positively charged area is composed of K45 and R46, playing an essential role in binding to CCR1.
Moreover, the spatial model displays that binding sites are located on the 40s ring and exposure to the surface of vMIP-II, contributing the binding sites to well combine with CCR1 ( Figure 2A ). According to the results of bioinformatic analysis, C18P was screened to be the object of present study. Pepsin (pH > 2) was chosen to digest vMIP-II in the following procedures. The structure of C18P was predicted using Vector NTI Advance software as shown in Figure 2B . The picture shown also presents that K45 and R46 are located on the surface of the molecule. 
Detection of C18P
The purity of peptide C18P was tested more than 95 % using high performance liquid chromatography. Mass spectrometry was utilized to verify the sequence of C18P. The molecular weight of C18P was calculated as 2133.96, which is consistent with the theoretical value.
Identification of C18P
Radioligand binding assays using human CCR1-transfected HEK293 cells were applied to identify the potency of C18P to inhibit 
C18P inhibits PBMCs chemotaxis
C18P was validated to lack cytotoxicity towards PMBCs, with survival rate of each treatment group > 80 %. To determine whether the C18P possesses immunogenicity, potential of C18P to induce PBMCs migration was examined in the chemotaxis assay. The chemotaxis indexes of all groups were < 2 (data not shown) indicating that the C18P lacked chemotactic capability (immunogenicity) from a perspective of statistic. The results correspond with those of [ 35 S]GTPγS binding experiment. Ability of C18P for inhibition of chemotaxis mediated by CCR1 was investigated further. As shown in Figure 3C , chemotaxis induced by HCC-1, MIP-1α and RANTES were strongly inhibited by C18P in a concentration-dependent manner, with IC 50 values of 23, 25 and 13.1 ng/ml, respectively. C18P did not have the potential to block PBMCs migration induced by ligands specific for non-CCR1 receptors (data not shown, Table 1 ), which was consistent with the results of radioligand binding assays. Nothing was added to control group. 10 ng/ml ligands and 100 ng/ml C18P were used in group ligand and group C18P, respectively. The last group was handled with 100 ng/ml C18P for 30 min before the experiments; *p < 0.05, compared with ligand group; **p < 0.01, compared with control group.
Effect of C18P on intracellular calcium mobilization
To assess the effect of C18P on CCR1, changes of intracellular Ca 2+ concentration in PBMCs were measured. We characterized whether C18P have the potential to induce intracellular calcium mobilization.
In the study, different concentrations of C18P had no direct effect on intracellular Ca 2+ concentration (data not shown). In addition, C18P failed to inhibit calcium mobilization stimulated by ligands specific for non-CCR1 receptors (data not shown, Table  1 ).These results were consistent with those of above-mentioned studies. In contrast, as shown in Figure 3D , calcium mobilization induced by CCR1 ligands, such as HCC-1, MIP-1α, RANTES, MCP-2, MCP-4, were dramatically blocked by C18P (100 ng/ml). C18P had no noticeable influence on intracellular calcium mobilization, being identical to the results of initial step of these experiments.
DISCUSSION
Since the initial identification of CCR1 as a receptor for the chemokines MIP-1α and RANTES [15] , the biology around CCR1 has been widely investigated over the last decades. A large number of studies have been published to support CCR1 as an attractive therapeutic target associating with leukocyte infiltration modulation and autoimmune diseases development.
Up to now, there have been a variety of small molecule antagonists of CCR1 entering phases of clinical studies, such as MLN3897 and CP-481715 [16, 17] . These antagonists bind to chemokine receptors, but do not initiate cytoplasmic signal transduction cascades. Normal physiological functions of chemokine receptors can be inhibited by these antagonists. Screening of antagonists for their ability to bind to chemokine receptors is an important consideration when developing anti-inflammatory therapies. Therefore, a novel and functional antagonist peptide, C18P, that can bind to CCR1 and inhibit ligand/receptor interaction, G-protein signaling, cell migration, and calcium mobilization, is described here.
In this contribution, the conserved residues, K45 and R46, were postulated to play an essential role in CCR1 binding owing to their favorable spatial location. C18P containing two conserved residues was screened from the peptide library, which was set up by collecting all peptide fragments derived from simulated peptide-cutting vMIP-II for the first time. In addition, C18P has potential to act as an orally drug from the perspective of administration due to its corresponding protease, pepsin. Given the importance of molecular conformation in terms of biological activity [18] , C18P structural model generated from the crystal structure of vMIP-II was built up. Overall, the findings are consistent with the prediction, proving that bioinformatics method was feasible to predict receptor binding site. Digestion based on simulated peptide-cut and utilized in practice was validated to be workable.
In our studies, C18P was assessed to be a specific and competitive antagonist peptide of human CCR1. [19] , was blocked by C18P with higher IC 50 but at concentration analogous to that necessary for inhibition of radioligand binding and chemotaxis. C18P did not be regarded as an intrinsic agonist because of failing to induce chemotaxis and calcium mobilization. Moreover, C18P also lacked potency to directly block cell migration and intracellular Ca 2+ concentration elevation induced by various specific ligands for non-CCR1 receptors.
Furthermore, studies of the effect of C18P on chemotaxis and calcium mobilization showed that treatment with C18P can efficiently inhibit PBMCs migration and elevation of Ca 2+ concentration induced by CCR1 ligands, which further indicate the CCR1 antagonist role of C18P. The result of calcium mobilization is supported by a previous study which demonstrated that chemokines can increase intracellular Ca 2+ concentration [2] . As such, it is reasonable to conclude that C18P is acting specifically against CCR1 and exerts its function to block cell activity induced by CCR1 ligands.
CONCLUSION
The findings of this study highlight a novel and specific small molecule antagonist peptide of CCR1 derived from vMIP-II, and uncover that C18P may be developed to be an oral antagonist peptide. This work further shows that simulated peptide-cut of vMIP-II based on bioinformatics can be achieved in reality. All the results demonstrate that peptide C18P is an antagonist of CCR1, and a potential candidate for the treatment of multiple diseases, including inflammation and rheumatoid arthritis.
